393-P: Technology Use and Hypoglycemia in Type 1 Diabetes: Insights from the BETTER Registry

The BETTER registry launched in April 2019 aims to understand the burden (frequency, severity) of hypoglycemia from people with T1D’s perspective and to evaluate the role of technologies in its prevention and management. Methods: BETTER registry includes several online surveys and is being conducted in Quebec, Canada. Preliminary results of the 2ndsurvey about technology use, CSII and FGM/CGM, in relation to hypoglycemia are reported. Results: By Dec 2019, 457 persons with T1D (> 14 y.o.) have completed the 2ndsurvey (44.0±15.7 y.o., 67.2 % females, 48.0% CSII users, 80% FGM/CGM users in past 12 months). Main reasons for opting for technology: A) CSII (n=219): glucose control with exercise (72.6%), elevated HbA1c (42.9%), nocturnal hypoglycemia (35.2%) as well as overall hypoglycemia severity and frequency (26.0%). Interestingly, 65.3% reported less hypoglycemia after adopting CSII. B) FGM/CGM (n=365): easier to follow glucose levels (77.5%), stop/reduce capillary measurements (69%), easier glucose control with exercise (68.5%). Table1 shows comparisons between technology users vs. non users: CSII and FGM/CGM users reported better glucose control, more hypoglycemia episodes (probably due to better diagnosis) that are corrected at higher BG levels. Conclusion: This database will improve the understanding of technologies roles in hypoglycemia detection, prevention and treatment to optimize their use. Disclosure N. Taleb: None. K. Desjardins: None. S. Haag: None. M. Prevost: None. R. Rabasa-Lhoret: Advisory Panel; Self; AstraZeneca, Eli Lilly and Company, Insulet Corporation, Janssen Pharmaceuticals, Inc. Board Member; Self; Merck & Co., Inc., Sanofi. Research Support; Self; Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk A/S, Sanofi. A. Brazeau: None. Funding Canadian Institutes of Health Research (JT1-157204); JDRF (4-SRA-2018-651-Q-R)